

Special Issue

2020 Update on the Management of Thyroid Cancer

Message from the Guest Editor

During the past several years, the management of thyroid cancers has moved toward individualized care based on adequate risk stratification systems. A rapid increase in the incidence of small, nonlethal papillary thyroid carcinoma has been reported from many developed countries, raising a modern issue of overdiagnosis and overtreatment of those carcinomas. In addition, the recent advent of molecular diagnostic tools is also expected to reduce unnecessary surgeries for patients with indeterminate thyroid nodules. On the other hand, the treatment outcomes of nonradioactive iodine avid, progressive differentiated thyroid carcinoma and anaplastic thyroid carcinoma are still challenging. In this trend of personalized medicine, the importance of patient-reported outcome studies has been increasing. In this Special Issue, experts will review the current management of patients with the wide spectrum of thyroid cancer.

Guest Editor

Prof. Iwao Sugitani

Department of Endocrine Surgery, Nippon Medical School Graduate School of Medicine, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8603 Japan

Deadline for manuscript submissions

closed (31 March 2021)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/48213

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)